ArticleMedicine2026
A retrospective comparative study on the effects of denosumab combined with calcium and vitamin D versus calcium and vitamin D alone on bone remodeling markers in patients with osteoporotic fractures.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to compare and analyze the effects of denosumab combined with calcium and vitamin D versus calcium and vitamin D alone on bone remodeling markers and bone mineral density (BMD) in patients with osteoporotic fractures. This single-center retrospective comparative study included patients with osteoporotic fractures admitted between January 2022 and January 2024. According to the treatment regimen, patients were divided into the denosumab group (subcutaneous denosumab every 6 months plus oral calcium and vitamin D supplementation) and the calcium plus vitamin D (CaD) group (oral calcium and vitamin D supplementation only). Propensity score matching was used to balance baseline characteristics, with 60 cases in each group. Bone remodeling markers (β-isomerized C-terminal telopeptide of type I collagen [β-CTX], procollagen type I N-terminal propeptide [P1NP], bone-specific alkaline phosphatase, osteocalcin), BMD changes, and safety profiles were compared between the 2 groups before treatment, and at 6 and 12 months after treatment. After treatment, the levels of the bone resorption marker β-CTX and the bone formation marker P1NP were significantly reduced in the denosumab group, and remained significantly lower than those in the CaD group at all time points (time, group, and interaction effects all P < .001). After 12 months of treatment, BMD increases in the lumbar spine and femoral neck were 8.8% and 7.3% respectively in the denosumab group, significantly higher than in the CaD group (2.6% and 2.2%) (P < .01 for both group and interaction effects). Correlation analysis showed that in the denosumab group, the decreases in β-CTX and P1NP were significantly negatively correlated with BMD improvements in the lumbar spine and femoral neck (r = -0.33 to -0.42, P < .05). The overall incidence of adverse events did not differ significantly between the 2 groups (13.3% vs 8.3%, P > .05), and all events were mild. For patients with osteoporotic fractures, denosumab combined with calcium and vitamin D supplementation is more effective in suppressing bone turnover and improving bone mineral density than calcium and vitamin D alone, without increasing significant safety risks. Bone remodeling markers β-CTX and P1NP may serve as potential reference indicators for evaluating the therapeutic efficacy of denosumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.